PellePharm Overview
- Founded
-
2012

- Status
-
Private
- Employees
-
8

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$70M
- Investors
-
8
PellePharm General Information
Description
Developer of skin cancer therapeutics designed to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.
Contact Information
Website
www.pellepharm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
- 101 Mission Street
- Suite 1950
- San Francisco, CA 94105
- United States
PellePharm Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Later Stage VC | 20-Nov-2018 | $70M | 00000 | Completed | Clinical Trials - Phase 3 | |
5. Later Stage VC (Series C) | 18-Jun-2018 | 00.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 3 |
4. Debt - General | 29-Mar-2018 | 00.00 | 000.00 | Completed | Clinical Trials - Phase 3 | |
3. Early Stage VC (Series B2) | 31-Jul-2017 | 0000 | 000.00 | 0000 | Completed | Clinical Trials - Phase 3 |
2. Early Stage VC (Series B) | 23-Jul-2015 | $4.55M | $7.67M | 000.00 | Completed | Startup |
1. Early Stage VC (Series A) | 11-May-2015 | $3.12M | $3.12M | 00.00 | Completed | Startup |
PellePharm Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Series B2 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B | 3,888,889 | $0.000100 | $0.09 | $1.17 | $1.17 | 1x | $1.17 | 8.67% |
Series A | 3,712,649 | $0.000100 | $0.84 | $0.84 | 1x | $0.84 | 8.27% |
PellePharm Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of skin cancer therapeutics designed to mitigate the tumor burden with basal cell carcinomas. The company's th
Drug Discovery
San Francisco, CA
8
As of 2021
00000
0000000000 0
00000
PellePharm Competitors (9)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Azitra | Venture Capital-Backed | Branford, CT | 00 | 000.00 | 0000000000 0 | 000.00 |
00000 00000 | Formerly VC-backed | San Francisco, CA | 0 | 000.00 | 000000&0 | 000.00 |
0-00000000 | Venture Capital-Backed | Beerse, Belgium | 00 | 00.000 | 0000000000 | 00.000 |
00000000 000000000 | Venture Capital-Backed | La Jolla, CA | 0 | 000 | 00000000000 | 000 |
0000000 0000000000 | Formerly VC-backed | Westlake Village, CA | 000 | 00000 | 000000000 | 00000 |
PellePharm Patents
PellePharm Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170231968-A1 | Method for relief of and treatment of pruritus | Abandoned | 11-Feb-2016 | 00000000000 |
PellePharm Executive Team (6)
PellePharm Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Anders Kronborg | Self | Board Member | 000 0000 |
Eric Aguiar MD | Aisling Capital | Board Observer | 000 0000 |
Frank McCormick Ph.D | Self | Board Member | 000 0000 |
Jean Tang MD | PellePharm | Co-Founder, Board Member & Medical Advisor | 000 0000 |
Katrin Andreasson | PellePharm | Board Member | 000 0000 |
PellePharm Signals
PellePharm Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
LEO Pharma | PE-Backed Company | Minority | 000 0000 | 000000 0 | |
Aisling Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
EcoR1 Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Mark De Souza | Angel (individual) | Minority | 000 0000 | 000000 0 | |
BridgeBio | Corporation | Minority | 000 0000 | 000000 0 |